new formulations of Actonel and Fosamax and a new bisphosphonate called Reclast

View the FDA's preliminary statement concerning bisphosphonates and atrial fibrillation

Drug companies will promote new formulations of Actonel and Fosamax and a new bisphosphonate called Reclast.

It's a competitive market. There are a huge number of potential patients...and big money is at stake.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote